keyword
MENU ▼
Read by QxMD icon Read
search

Rosuvastatin

keyword
https://www.readbyqxmd.com/read/29232752/simultaneous-determination-of-rosuvastatin-rosuvastatin-5%C3%A2-s-lactone-and-n-desmethyl-rosuvastatin-in-human-plasma-by-uplc-ms-ms-and-its-application-to-clinical-study
#1
Xue Bai, Xi-Pei Wang, Guo-Dong He, Bin Zhang, Min Huang, Jia-Li Li, Shi-Long Zhong
Objective A rapid and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay was developed and validated for the simultaneous quantification of rosuvastatin (RST), rosuvastatin-5 S-lactone (RSTL), and N-desmethyl rosuvastatin (DM-RST) in human plasma. Methods Sample was prepared by liquid-liquid extraction with ethyl acetate from 100 μL acidulated buffered plasma. Then analytes were chromatographically separated using an Acquity UPLC HSS T3 column (3.0 mm×100 mm, 1...
December 12, 2017: Drug Research
https://www.readbyqxmd.com/read/29225188/rosuvastatin-improves-myocardial-hypertrophy-after-hemodynamic-pressure-overload-via-regulating-the-crosstalk-of-nrf2-are-and-tgf-%C3%AE-smads-pathways-in-rat-heart
#2
Pengbo Wang, Lin Luo, Qiusheng Shen, Gaoyong Shi, Anaz Mohammed, Songshi Ni, Xiang Wu
Left ventricular hypertrophy is more commonly associated with hemodynamic overload imposed by hypertension or volume overload. Transforming growth factor β (TGF-β) is involved in the cardiac hypertrophy and fibrosis of the left ventricle. The fact that TGF-β1 and the nuclear factor erythroid 2-related factor 2 (Nrf2) both become up-regulated upon persistent vessel overload suggests that these two factors may virtually impact on their signaling pathways. In this research, 40 rats were divided into sham group, model group, rosuvastatin low and high dose group...
December 7, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29223557/efficacy-and-safety-of-adding-omega-3-fatty-acids-in-statin-treated-patients-with-residual-hypertriglyceridemia-romantic-rosuvastatin-omacor-in-residual-hypertriglyceridemia-a-randomized-double-blind-and-placebo-controlled-trial
#3
Chee Hae Kim, Kyung Ah Han, Jaemyung Yu, Sang Hak Lee, Hui Kyung Jeon, Sang Hyun Kim, Seok Yeon Kim, Ki Hoon Han, Kyungheon Won, Dong-Bin Kim, Kwang-Jae Lee, Kyungwan Min, Dong Won Byun, Sang-Wook Lim, Chul Woo Ahn, SeongHwan Kim, Young Joon Hong, Jidong Sung, Seung-Ho Hur, Soon Jun Hong, Hong-Seok Lim, Ie Byung Park, In Joo Kim, Hyoungwoo Lee, Hyo-Soo Kim
PURPOSE: The purpose of this study was to examine the efficacy and safety of adding ω-3 fatty acids to rosuvastatin in patients with residual hypertriglyceridemia despite statin treatment. METHODS: This study was a multicenter, randomized, double-blind, placebo-controlled study. After a 4-week run-in period of rosuvastatin treatment, the patients who had residual hypertriglyceridemia were randomized to receive rosuvastatin 20 mg/d plus ω-3 fatty acids 4 g/d (ROSUMEGA group) or rosuvastatin 20 mg/d (rosuvastatin group) with a 1:1 ratio and were prescribed each medication for 8 weeks...
December 6, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29218707/food-effect-on-rosuvastatin-disposition-and-low-density-lipoprotein-cholesterol
#4
Cheynne C McLean, Wendy A Teft, Bridget L Morse, Steven E Gryn, Robert A Hegele, Richard B Kim
Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and hepatic transporter-mediated accumulation in the liver enhances its efficacy. Current guidelines indicate no preference for fed or fasted rosuvastatin administration. We investigated the association between food intake and rosuvastatin disposition in healthy subjects and low-density lipoprotein cholesterol (LDL-C) lowering effects among patients taking rosuvastatin. We demonstrate administration with food resulted in a near 40% reduction of rosuvastatin exposure in healthy Asian (n=12) and Caucasian (n=11) subjects...
December 8, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29212823/quantitative-expression-of-hepatobiliary-transporters-and-functional-uptake-of-substrates-in-hepatic-2d-sandwich-cultures-a-comparative-evaluation-of-upcyte-and-primary-human-hepatocytes
#5
Michelle Schaefer, Gaku Morinaga, Akiko Matsui, Gerhard Schanzle, Daniel Bischoff, Roderich D Sussmuth
Deficient functional expression of drug transporters incapacitates most hepatic cell lines as reliable tool for evaluating transporter-mediated drug-drug interactions. Recently, genetically-modified cells, referred to as upcyte hepatocytes, have emerged as an expandable, non‑cancerous source of human hepatic cells. Herein, we quantified mRNA and protein levels of key hepatobiliary transporters and assessed associated uptake activity in short- and long-term cultures of upcyte human hepatocytes (UHH), in comparison to cryopreserved primary human hepatocytes (cPHH)...
December 6, 2017: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/29212544/plaque-volume-and-plaque-risk-profile-in-diabetic-vs-non-diabetic-patients-undergoing-lipid-lowering-therapy-a-study-based-on-3d-intravascular-ultrasound-and-virtual-histology
#6
Tomas Kovarnik, Zhi Chen, Gary S Mintz, Andreas Wahle, Kristyna Bayerova, Ales Kral, Martin Chval, Karel Kopriva, John Lopez, Milan Sonka, Ales Linhart
BACKGROUND: Coronary atherosclerosis progresses faster in patients with diabetes mellitus (DM) and causes higher morbidity and mortality in such patients compared to non-diabetics ones (non-DM). We quantify changes in plaque volume and plaque phenotype during lipid-lowering therapy in DM versus non-DM patients using advanced intracoronary imaging. METHODS: We analyzed data from 61 patients with stable angina pectoris included to the PREDICT trial searching for prediction of plaque changes during intensive lipid-lowering therapy (40 mg rosuvastatin daily)...
December 7, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29211309/statins-in-nonsurgical-and-surgical-periodontal-therapy-a-systematic-review-and-meta-analysis-of-preclinical-in-vivo-trials
#7
REVIEW
K Bertl, I Steiner, N Pandis, K Buhlin, B Klinge, A Stavropoulos
The cholesterol-lowering drugs, statins, possess anti-inflammatory, antimicrobial and pro-osteogenic properties, and thus have been tested as an adjunct to periodontal treatment. The present systematic review aimed to answer the following focused research question: What is the effect of local and/or systemic statin use on periodontal tissues in preclinical in vivo studies of experimentally induced periodontitis (EIP) and/or acute/chronified periodontal defect (ACP) models? A literature search (of Medline/PubMed, Embase/Ovid, CENTRAL/Ovid) using the following main eligibility criteria was performed: (i) English or German language; (ii) controlled preclinical in vivo trials; (iii) local and/or systemic statin use in EIP and/or ACP models; and (iv) quantitative evaluation of periodontal tissues (i...
December 6, 2017: Journal of Periodontal Research
https://www.readbyqxmd.com/read/29209775/effect-of-aggressive-lipid-lowering-treatment-with-rosuvastatin-on-vascular-endothelium-function-evaluation-of-vascular-endothelium-function-earth-study
#8
Tadateru Takayama, Takafumi Hiro, Shunichi Yoda, Daisuke Fukamachi, Hironori Haruta, Takaaki Kogo, Takashi Mineki, Hironobu Murata, Toru Oshima, Atsushi Hirayama
Vascular endothelial dysfunction plays an important role in the process of atherosclerosis up to the final stage of plaque rupture. Vascular endothelial dysfunction is reversible, and can be recovered by medications and life-style changes. Improvement in endothelial function may reduce cardiovascular events and improve long-term prognosis. A total of 50 patients with stable angina and dyslipidemia were enrolled, including patients who had not received prior treatment with statins and had serum LDL-C levels ≥ 100 mg/dL, and patients who had previously received statin treatment...
December 5, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/29201198/comparison-of-the-effect-of-rosuvastatin-versus-rosuvastatin-ezetimibe-on-markers-of-inflammation-in-patients-with-acute-myocardial-infarction
#9
Yizhi Ren, Hao Zhu, Zhongguo Fan, Yali Gao, Nailiang Tian
Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP), and the addition of ezetimibe to statins further reduces LDL-C and hsCRP. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a potentially important pathogenic factor participating in the progression of atherosclerosis. The aim of current study was to investigate how the addition of ezetimibe to rosuvastatin treatment affects reductions in LDL-C, hsCRP and Lp-PLA2 in patients with acute myocardial infarction (AMI)...
November 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29189310/muscle-damage-due-to-fusidic-acid-statin-interaction-review-of-75-cases-from-the-french-pharmacovigilance-database-and-literature-reports
#10
Maxime Bataillard, Marie-Noëlle Beyens, Geneviève Mounier, Delphine Vergnon-Miszczycha, Haleh Bagheri, Pascal Cathebras
BACKGROUND/AREA OF UNCERTAINTY: Statins, which reduce cardiovascular risk in both primary and secondary prevention, are one of the most widely prescribed therapeutic classes in the world. Usually well-tolerated, statin-associated muscle symptoms are a well-known adverse effect. Fusidic acid (FA) is a bacteriostatic antibiotic of interest in the treatment of methicillin-resistant Staphylococcus aureus infections. Cases of rhabdomyolysis, sometimes fatal, have been reported after coprescription of FA and a statin...
November 9, 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29185103/unraveling-the-interaction-of-aspirin-ticagrelor-and-rosuvastatin-on-the-progression-of-atherosclerosis-and-inflammation-in-diabetic-mice
#11
Yumei Ye, Sven Nylander, Yochai Birnbaum
PURPOSE: We explored the effects of rosuvastatin, aspirin, ticagrelor, and clopidogrel, alone or in combinations on the progression of atherosclerosis and inflammasome activation in diabetic mice. Statins and ticagrelor increase the production of 15-epi-lipoxin A4 via cyclooxygenase-2. Aspirin alone increases 15-epi-lipoxin A4, but when combined with statins, cyclooxygenase-2 is completely blocked. METHODS: ApoE-/-/db+/db+ double-knockout mice received rosuvastatin (5 mg/kg/day), aspirin (25 mg/kg/day), ticagrelor (300 mg/kg/day), clopidogrel (75 mg/kg/day), or their combination for 14 weeks...
November 28, 2017: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29174015/effect-of-statin-therapy-on-the-prevention-of-new-onset-acute-coronary-syndrome-in-patients-with-rheumatoid-arthritis
#12
Chen-Yu Huang, Ting-Tse Lin, Yao-Hsu Yang, Lian-Yu Lin, Chia-Ti Tsai, Juey-Jen Hwang, Pau-Chung Chen, Jiunn-Lee Lin
BACKGROUND: The aim of this study is to investigate whether statin therapy can reduce new-onset acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA). METHODS: We used a database from the Registry for Catastrophic Illness from the National Health Research Institute (NHRI) in Taiwan. All RA patients aged 18 or older, diagnosed between 1995 and 2013, without previous cardiovascular events were included. We divided participants into quartiles according to the accumulated statin equivalent dosage and tertiles of period of days of statin treatment to examine the possible dose-response effect...
November 11, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29162602/rosuvastatin-reduces-aortic-sinus-and-coronary-artery-atherosclerosis-in-sr-b1-scavenger-receptor-class-b-type-1-apoe-apolipoprotein-e-double-knockout-mice-independently-of-plasma-cholesterol-lowering
#13
Pei Yu, Ting Xiong, Christine B Tenedero, Paul Lebeau, Ran Ni, Melissa E MacDonald, Peter L Gross, Richard C Austin, Bernardo L Trigatti
OBJECTIVE: Rosuvastatin has been widely used in the primary and secondary prevention of coronary heart disease. However, its antiatherosclerotic properties have not been tested in a mouse model that could mimic human coronary heart disease. The present study was designed to test the effects of rosuvastatin on coronary artery atherosclerosis and myocardial fibrosis in SR-B1 (scavenger receptor class B type 1) and apoE (apolipoprotein E) double knockout mice. APPROACH AND RESULTS: Three-week-old SR-B1(-/)(-)/apoE(-/)(-) mice were injected daily with 10 mg/kg of rosuvastatin for 2 weeks...
November 21, 2017: Arteriosclerosis, Thrombosis, and Vascular Biology
https://www.readbyqxmd.com/read/29162214/pharmacokinetics-and-bioequivalence-of-a-rosuvastatin-ezetimibe-fixed-dose-combination-tablet-versus-single-agents-in-healthy-male-subjects%C3%A2
#14
Woo Youl Kang, Sook Jin Seong, Boram Ohk, Mi-Ri Gwon, Bo Kyung Kim, Sookie Na, Hyun-Ju Kim, Young-Ran Yoon, Hae Won Lee
OBJECTIVE: The pharmacokinetic profiles and bioequivalence of a new rosuvastatin/ezetimibe fixed-dose combination (FDC; NVP-1205) vs. rosuvastatin and ezetimibe concomitantly administered as single agents were evaluated. MATERIALS AND METHODS: In this open-label, single-dose, crossover study (NCT02029625), eligible subjects were randomly assigned in a 1 : 1 ratio to receive a single dose of rosuvastatin (10 mg) with ezetimibe (10 mg) as either a FDC or as single agents concomitantly administered under fasted conditions, followed by a 2-week washout period and administration of the alternate formulation...
November 22, 2017: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29155776/differential-effects-of-lipid-lowering-drugs-in-modulating-morphology-of-cholesterol-particles
#15
Shanmugavel Madasamy, David Liu, Jason Lundry, Benjamin Alderete, Raymond Kong, J Paul Robinson, Alan H B Wu, Edward P Amento
Treatment of dyslipidemia patients with lipid-lowering drugs leads to a significant reduction in low-density lipoproteins (LDL) level and a low to moderate level of increase in high-density lipoprotein (HDL) cholesterol in plasma. However, a possible role of these drugs in altering morphology and distribution of cholesterol particles is poorly understood. Here, we describe the in vitro evaluation of lipid-lowering drug effects in modulating morphological features of cholesterol particles using the plaque array method in combination with imaging flow cytometry...
November 10, 2017: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/29150250/a-randomized-multicenter-double-blind-placebo-controlled-study-to-evaluate-the-efficacy-and-the-tolerability-of-a-triple-combination-of-amlodipine-losartan-rosuvastatin-in-patients-with-comorbid-essential-hypertension-and-hyperlipidemia
#16
Hae-Young Lee, Seok-Yeon Kim, Kee-Joon Choi, Byung-Su Yoo, Dong-Hun Cha, Hae Ok Jung, Dong-Ryeol Ryu, Joon Hyouk Choi, Kwang Je Lee, Tae Ho Park, Ju Hyeon Oh, Sang Min Kim, Ji-Yong Choi, Kye Hun Kim, Jaemin Shim, Woo-Shik Kim, Si-Wan Choi, Dae-Gyun Park, Pil-Sang Song, Taek-Jong Hong, Moo-Yong Rhee, Seung-Woon Rha, Seung Woo Park
PURPOSE: The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia. METHODS: A randomized, multicenter, double-blind, placebo-controlled study was conducted. Eligible patients with hypertension and a sitting diastolic blood pressure (SiDBP) of >90 mm Hg and LDL-C levels <250mg/dL were screened. After a 4-week run-in period with therapeutic lifestyle changes and losartan potassium 100mg once daily, patients who met both blood pressure criteria (80 mm Hg ≤ SiDBP < 110 mm Hg) and the LDL-C level criteria (defined in the National Cholesterol Education Program Adult Treatment Panel III cardiovascular risk categories) were randomized to 1 of 3 groups and treated once daily for 8 weeks: losartan potassium 100mg + rosuvastatin 20mg treatment (L/R 100/20) group, amlodipine camsylate 5mg + losartan potassium 100mg treatment (A/L 5/100) group, and amlodipine 5mg+ losartan potassium 100mg + rosuvastatin 20mg (A/L/R 5/100/20) group...
November 14, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29148854/comparative-effectiveness-of-lipid-lowering-treatments-to-reduce-cardiovascular-disease
#17
Dong-Churl Suh, Scott K Griggs, Emmett R Henderson, Seung-Mi Lee, Taehwan Park
With the advent of a new drug class - the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, patients have another treatment option for lowering their high levels of low-density lipoprotein cholesterol (LDL-C) in recent years. The objective of this study was to systematically review the cost-effectiveness of lipid-lowering agents such as statins, ezetimibe, and PCSK9 inhibitors. Areas covered: Based on PubMed, Embase, and Cochrane Database of Systematic Reviews, we identified a total of 29 relevant articles...
November 17, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29123380/development-of-%C3%AE-cyclodextrin-based-hydrogel-microparticles-for-solubility-enhancement-of-rosuvastatin-an-in-vitro-and-in-vivo-evaluation
#18
Rai Muhammad Sarfraz, Mahmood Ahmad, Asif Mahmood, Muhammad Rouf Akram, Asad Abrar
The aim of this study was to enhance the solubility of rosuvastatin (RST) calcium by developing β-cyclodextrin-g-poly(2-acrylamido-2-methylpropane sulfonic acid [AMPS]) hydrogel microparticles through aqueous free-radical polymerization technique. Prepared hydrogel microparticles were characterized for percent entrapment efficiency, solubility studies, Fourier transform infrared spectroscopy, differential scanning calorimetry, thermal gravimetric analysis, powder X-ray diffraction, scanning electron microscopy, zeta size and potential, swelling and release studies...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29121934/effect-of-rosuvastatin-on-fasting-and-postprandial-endothelial-biomarker-levels-and-microvascular-reactivity-in-patients-with-type-2-diabetes-and-dyslipidemia-a-preliminary-report
#19
Kyoung Min Kim, Kyong Yeun Jung, Han Mi Yun, Seo Young Lee, Tae Jung Oh, Hak Chul Jang, Soo Lim
BACKGROUND: The cardiovascular benefits of statins have been proven, but their effect on circulation in small vessels has not been examined fully. We investigated the effect of 20 mg rosuvastatin on biomarkers, including paraoxonase-1 (PON-1) and asymmetric dimethylarginine (ADMA), and on microvascular reactivity. METHOD: We enrolled 20 dyslipidemic patients with type 2 diabetes and 20 age- and body mass index (BMI)-matched healthy controls. Rosuvastatin (20 mg/day) was given to the patient group for 12 weeks...
November 9, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29119729/efficacy-of-statin-delivery-as-an-adjunct-to-scaling-and-root-planing-in-the-treatment-of-chronic-periodontitis-a-meta-analysis
#20
REVIEW
Zohaib Akram, Fahim Vohra, Fawad Javed
The action of statins in stimulating bone formation and having other pleiotropic effects, such as anti-inflammatory and immunomodulatory effects, has justified their use as an adjunct to scaling and root planing (SRP) in the treatment of chronic periodontitis (CP). The aim of the present study was to evaluate the efficacy of statin delivery as an adjunct to SRP in the treatment of CP. Electronic searches were conducted using the following databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Oral Health Group Trials Register, up until July 2017...
November 9, 2017: Journal of Investigative and Clinical Dentistry
keyword
keyword
6832
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"